



### Market data

EPIC/TKR	AVP
Price (p)	50.7
12m High (p)	64.8
12m Low (p)	9.5
Shares (m)	156.5
Mkt Cap (£m)	79.4
EV (£m)	72.4
Free Float*	47%
Market	AIM

\*As defined by AIM Rule 26

### Description

Advanced Oncotherapy (AVO) is developing next-generation proton therapy systems for use in radiation treatment of cancers. The first system is expected to be installed in Harley Street, London, during 2019; it will be operated through a JV with Circle Health.

### Company information

Exec. Chairman	Michael Sinclair
CEO	Nicolas Serandour

+44 203 617 8728

[www.advancedonctherapy.com](http://www.advancedonctherapy.com)

### Key shareholders

Board & Management	15.4%
Yantai CIPU	28.9%
Brahma AG	5.8%
AB Segulah	4.2%
M3T Pte Ltd	3.3%
MK Trust	3.1%

### Diary

Oct'18	Interims
Mch'19	Finals
1H'19	Harley Street ready

### Analysts

Martin Hall	020 7194 7632	<a href="mailto:mh@hardmanandco.com">mh@hardmanandco.com</a>
Dorothea Hill	020 7194 7626	<a href="mailto:dmh@hardmanandco.com">dmh@hardmanandco.com</a>
Grégoire Pavé	020 7194 7628	<a href="mailto:gp@hardmanandco.com">gp@hardmanandco.com</a>

## ADVANCED ONCOTHERAPY

### Treatment planning system agreement

AVO's goal is to deliver a more affordable, novel, proton-based radiotherapy system, based on state-of-the-art technology developed originally at the world-renowned CERN. Major technical milestones were achieved in 2017 and the company remains on track with its development plan. Confidence has been boosted greatly by the integration of the first three structures and overcoming the technical challenge of accelerating the proton beam. With the hardware progressing well, AVO has announced a strategic collaboration with RaySearch for the development of the treatment planning system for LIGHT in Harley Street.

- **Strategy:** To develop a compact and modular proton therapy (PT) system at an affordable price for the payor, financially attractive to the operator, and generating superior patient outcomes. AVO benefits from the technology know-how developed by ADAM, Geneva, and relies on a base of world-class suppliers.
- **Collaboration agreement:** The strategic collaboration agreement with RaySearch will enable AVO to equip the LIGHT system at Harley Street with the full spectrum of the company's RayStation software functionality for treatment planning, encompassing patient positioning through to treatment solutions.
- **RaySearch:** RaySearch has a presence in 2,600 clinics in 65 countries through licensing agreements with leading medical technology companies. It is the global leader in software solutions for radio and particle therapies and will provide AVO with its established RayStation software to control the LIGHT system.
- **Risks:** With the new funding secured, the visibility of the company and its ability to keep the pace of its development plan have improved. Execution risk remains, but the more complex technical challenges have been overcome, and integration of the remaining units follows known working prototypes.
- **Investment summary:** Demand for PT is increasing worldwide and the need for a small, flexible, affordable and close-to-patient machine is desirable. AVO has attracted strong partners and discussions with potential customers are advancing. Attention is focused on the construction timetable for the flagship Harley Street site and installation of the first LIGHT system. Forward planning to provide the software for controlling the LIGHT hardware is boosting confidence further.

### Financial summary and valuation

Year-end Dec (£m)	2015	2016	2017	2018E	2019E	2020E
Sales	0.0	0.0	0.0	0.0	0.0	4.6
Administration costs	-6.6	-11.2	-12.9	-12.4	-12.6	-12.8
Milestones/up-fronts	0.0	0.0	0.0	16.5	0.0	0.0
EBITDA	-6.4	-10.8	-12.6	4.5	-12.1	-12.3
Underlying EBIT	-6.6	-11.2	-12.9	4.1	-12.6	-12.8
Reported EBIT	-8.5	-13.1	-14.5	2.2	-14.6	-15.4
Underlying PBT	-6.7	-11.3	-14.9	1.4	-15.6	-15.8
Statutory PBT	-8.6	-13.2	-16.5	-0.5	-17.7	-18.5
Underlying EPS (p)	-7.1	-13.9	-15.6	2.8	-6.8	-6.6
Statutory EPS (p)	-12.3	-14.4	-18.9	1.6	-7.9	-7.9
Net (debt)/cash	8.0	0.9	-9.2	12.3	-5.3	-25.2
Capital increase	21.1	13.5	0.3	32.2	8.0	8.0

## Partnering with RaySearch

### Collaboration agreement for the TPS

As with all computer-assisted systems, the hardware is worthless without the appropriate software to control it. This is particularly true for radiotherapy, and even more so for proton therapy (PT), where patient position, imaging and the beam have to be measured, simulated and aligned extremely accurately – in the order of one millimetre – to maximise the positive effects of the proton and minimise the harm to healthy tissue. AVO has made sufficient progress with its hardware over the past 18 months, and this now requires the patient treatment planning system (TPS) to be considered.

AVO has selected the validated and established RayStation software solution to provide the TPS for LIGHT. RayStation is a flexible software system, easy to operate by the end-user, and compatible with most radiotherapy machines. The agreement provides AVO with the full spectrum of RayStation's functionality, integrating everything needed to operate a PT system. Currently, the collaboration agreement is only for the LIGHT machine to be installed at Harley Street.

RaySearch is the market-leading entity that provides its innovative RayStation software platform for patient planning solutions for flexible systems. RaySearch's software solutions have been installed in over 2,600 clinics in 65 countries through licensing agreements with leading medical technology companies. In the current year, RayStation has been used in 466 centres in 31 countries as the software controlling the TPS in oncology. Therefore, oncologists/radiologists around the world are familiar with this software package. RaySearch's products are being distributed through licensing agreements with leading medical radiation therapy (RT) companies such as Varian, IBA, Philips, Accuray and Hitachi-Mitsubishi.

#### *Treatment planning system*

The TPS is at the heart of RT systems and considered to be key to improved patient outcomes. It uses 3D image datasets of the patient's position and internal organ/tissue where the tumour/s is/are located. The system develops a complex plan for each patient to optimise the route of the beam line to access the tumour, as well as avoiding key organs that are sensitive to radiation. The software also estimates and processes the dose distribution and frequency in the patient's tissue, including variables such as tissue type (e.g. bone or lung vs. muscle) that require different energy levels.

#### *RayStation software features*

RayStation integrates all RaySearch's advanced treatment planning solutions into a flexible treatment planning system. It has been designed for 4-D adaptive RT as a built-in generic feature and it incorporates the latest techniques for PT, including the fast proton Monte Carlo dose engine used for modelling the proton beam. It also contains tools for multi-criteria optimisation, enabling a much more intuitive treatment planning process. The software uses a modular design to offer different combinations of its capabilities. It also includes functionality that can be used in other radiotherapy techniques for intensity-modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) optimisation, and highly accurate dose engines for particle therapies: photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability and flexibility.

## RaySearch's TPS



Source: RayStation product brochure 2018

The list of the different features included in the RayStation system is too long to be itemised, and software upgrades add new elements that follow requests from customers. In 2018, RaySearch released RayStation8, which will provide a new feature in artificial intelligence (AI). With the RayStation system, AVO will have access to the full spectrum of software possibilities, including the following:

- ▶ a fast proton Monte Carlo dose engine, which can be used for final dose computation and optimisation;
- ▶ robust 4D optimisation, which allows organ motion seen, for example, during patient breathing;
- ▶ linear energy transfer (LET) driven optimisation, which describes the action of radiation into matter;
- ▶ deformable registration, which allows, for example, weight loss and tumour shrinkage;
- ▶ dose accumulation for better results;
- ▶ plan adaptation;
- ▶ multi-criteria optimisation;
- ▶ automatic plan generation through Plan Explorer.

### What does the agreement mean for AVO?

The collaboration with RaySearch will provide AVO with almost turnkey software, which will require new development and customisation in order to maximise the potential of the LIGHT system's advanced capabilities. RayStation is already established in controlling PT systems from various competitors, giving confidence that RayStation can provide an adequate TPS solution for LIGHT. The system supports a full range of standard features used in PT, including pencil beam scanning, double scattering, uniform scanning, line scanning and wobbling. The system has been adopted by 43 particle centres in 14 countries. However, although RayStation will provide a faster, validated, alternative to bespoke software, in the longer term, we believe AVO will build its own TPS in order to maximise the distinct features of the LIGHT system. We noted, for example, that the use of the unique fast beam frequency at 200MHz will not be supported by RayStation.

# Disclaimer

Hardman & Co provides professional independent research services and all information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable. However, no guarantee, warranty or representation, express or implied, can be given by Hardman & Co as to the accuracy, adequacy or completeness of the information contained in this research and they are not responsible for any errors or omissions or results obtained from use of such information. Neither Hardman & Co, nor any affiliates, officers, directors or employees accept any liability or responsibility in respect of the information which is subject to change without notice and may only be correct at the stated date of their issue, except in the case of gross negligence, fraud or wilful misconduct. In no event will Hardman & Co, its affiliates or any such parties be liable to you for any direct, special, indirect, consequential, incidental damages or any other damages of any kind even if Hardman & Co has been advised of the possibility thereof.

This research has been prepared purely for information purposes, and nothing in this report should be construed as an offer, or the solicitation of an offer, to buy or sell any security, product, service or investment. The research reflects the objective views of the analyst(s) named on the front page and does not constitute investment advice. However, the companies or legal entities covered in this research may pay us a fixed fee in order for this research to be made available. A full list of companies or legal entities that have paid us for coverage within the past 12 months can be viewed at <http://www.hardmanandco.com/legal/research-disclosures>. Hardman may provide other investment banking services to the companies or legal entities mentioned in this report.

Hardman & Co has a personal dealing policy which restricts staff and consultants' dealing in shares, bonds or other related instruments of companies or legal entities which pay Hardman & Co for any services, including research. No Hardman & Co staff, consultants or officers are employed or engaged by the companies or legal entities covered by this document in any capacity other than through Hardman & Co.

Hardman & Co does not buy or sell shares, either for their own account or for other parties and neither do they undertake investment business. We may provide investment banking services to corporate clients. Hardman & Co does not make recommendations. Accordingly, they do not publish records of their past recommendations. Where a Fair Value price is given in a research note, such as a DCF or peer comparison, this is the theoretical result of a study of a range of possible outcomes, and not a forecast of a likely share price. Hardman & Co may publish further notes on these securities, companies and legal entities but has no scheduled commitment and may cease to follow these securities, companies and legal entities without notice.

The information provided in this document is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject Hardman & Co or its affiliates to any registration requirement within such jurisdiction or country.

Some or all alternative investments may not be suitable for certain investors. Investments in small and mid-cap corporations and foreign entities are speculative and involve a high degree of risk. An investor could lose all or a substantial amount of his or her investment. Investments may be leveraged and performance may be volatile; they may have high fees and expenses that reduce returns. Securities or legal entities mentioned in this document may not be suitable or appropriate for all investors. Where this document refers to a particular tax treatment, the tax treatment will depend on each investor's particular circumstances and may be subject to future change. Each investor's particular needs, investment objectives and financial situation were not taken into account in the preparation of this document and the material contained herein. Each investor must make his or her own independent decisions and obtain their own independent advice regarding any information, projects, securities, tax treatment or financial instruments mentioned herein. The fact that Hardman & Co has made available through this document various information constitutes neither a recommendation to enter into a particular transaction nor a representation that any financial instrument is suitable or appropriate for you. Each investor should consider whether an investment strategy of the purchase or sale of any product or security is appropriate for them in the light of their investment needs, objectives and financial circumstances.

This document constitutes a 'financial promotion' for the purposes of section 21 Financial Services and Markets Act 2000 (United Kingdom) ('FSMA') and accordingly has been approved by Capital Markets Strategy Ltd which is authorised and regulated by the Financial Conduct Authority (FCA).

No part of this document may be reproduced, stored in a retrieval system or transmitted in any form or by any means, mechanical, photocopying, recording or otherwise, without prior permission from Hardman & Co. By accepting this document, the recipient agrees to be bound by the limitations set out in this notice. This notice shall be governed and construed in accordance with English law. Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the FCA under registration number 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

(Disclaimer Version 8 – Effective from August 2018)

## Status of Hardman & Co's research under MiFID II

Some professional investors, who are subject to the new MiFID II rules from 3rd January, may be unclear about the status of Hardman & Co research and, specifically, whether it can be accepted without a commercial arrangement. Hardman & Co's research is paid for by the companies, legal entities and issuers about which we write and, as such, falls within the scope of 'minor non-monetary benefits', as defined in the Markets in Financial Instruments Directive II.

In particular, Article 12(3) of the Directive states: The following benefits shall qualify as acceptable minor non-monetary benefits only if they are: (b) 'written material from a third party that is commissioned and paid for by a corporate issuer or potential issuer to promote a new issuance by the company, or where the third party firm is contractually engaged and paid by the issuer to produce such material on an ongoing basis, provided that the relationship is clearly disclosed in the material and that the material is made available at the same time to any investment firms wishing to receive it or to the general public...'

The fact that Hardman & Co is commissioned to write the research is disclosed in the disclaimer, and the research is widely available.

The full detail is on page 26 of the full directive, which can be accessed here: <http://ec.europa.eu/finance/docs/level-2-measures/mifid-delegated-regulation-2016-2031.pdf>

In addition, it should be noted that MiFID II's main aim is to ensure transparency in the relationship between fund managers and brokers/suppliers, and eliminate what is termed 'inducement', whereby free research is provided to fund managers to encourage them to deal with the broker. Hardman & Co is not inducing the reader of our research to trade through us, since we do not deal in any security or legal entity.



[research@hardmanandco.com](mailto:research@hardmanandco.com)

35 New Broad Street  
London  
EC2M 1NH

+44(0)20 7194 7622

[www.hardmanandco.com](http://www.hardmanandco.com)